Armata Pharmaceuticals, Inc. (ARMP)
| Market Cap | 142.20M |
| Revenue (ttm) | 3.99M |
| Net Income (ttm) | -23.73M |
| Shares Out | 27.09M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,394 |
| Open | 5.43 |
| Previous Close | 5.42 |
| Day's Range | 5.05 - 5.68 |
| 52-Week Range | 2.82 - 6.50 |
| Beta | -0.11 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+52.4%) |
| Earnings Date | n/a |
About ARMP
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing propriet...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ARMP stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 52.38% from the latest price.
News
Recent Price Trend in Armata Pharmaceuticals, Inc. (ARMP) is Your Friend, Here's Why
Armata Pharmaceuticals, Inc. (ARMP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that pa...
Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs
MARINA DEL REY, Calif., Jan. 5, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific ba...
Wall Street Analysts Believe Armata Pharmaceuticals, Inc. (ARMP) Could Rally 47%: Here's is How to Trade
The mean of analysts' price targets for Armata Pharmaceuticals, Inc. (ARMP) points to a 46.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree...
Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therape...
MARINA DEL REY, Calif., Nov. 18, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific b...
What Makes Armata Pharmaceuticals, Inc. (ARMP) a New Buy Stock
Armata Pharmaceuticals, Inc. (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 15.38% and 23.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...
Armata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate Update
MARINA DEL REY, Calif., Nov. 10, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...
Armata Pharmaceuticals, Inc. (ARMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Armata Pharmaceuticals, Inc. (ARMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress
MARINA DEL REY, Calif., Nov. 4, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage t...
Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility
MARINA DEL REY, Calif., Nov. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific ba...
Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals
MARINA DEL REY, Calif., Oct. 28, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific b...
Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
MARINA DEL REY, Calif., Sept. 8, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...
Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0.00% and 42.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update
MARINA DEL REY, Calif., Aug. 12, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...
Will Armata Pharmaceuticals, Inc. (ARMP) Report Negative Q2 Earnings? What You Should Know
Armata Pharmaceuticals, Inc. (ARMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Armata Pharmaceuticals Announces Chief Executive Officer Transition
MARINA DEL REY, Calif., Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific ba...
Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference
MARINA DEL REY, Calif. , July 7, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...
Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update
MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage th...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Armata Pharmaceuticals Inc. for Potential Breaches ...
NEW YORK, May 13, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cla...
Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update
MARINA DEL REY, Calif., March 18, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva
MARINA DEL REY, Calif., March 17, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...
Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference
MARINA DEL REY, Calif., March 16, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...
Notable Insider Buys Seen In The Past Week: Green Brick, Intel, Teledyne And More
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Develop...
MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage t...